Evidence map›Paper›PMID 21901094›Full record

ArticlePLoS pathogens2011

A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia.

Jin Qiu, Katherine Cosmopoulos, Michiel Pegtel, Erik Hopmans, Paul Murray, Jaap Middeldorp, Michael Shapiro, David A Thorley-Lawson

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 137 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Jin QiuDept of Pathology, Tufts University School of Medicine, Boston, Massachusetts, United States of America.
Katherine Cosmopoulos
Michiel Pegtel
Erik Hopmans
Paul Murray
Jaap Middeldorp
Michael Shapiro
David A Thorley-Lawson
Tufts University · USAmsterdam UMC Location VUmc · NLUniversity of Birmingham · GB

Funding

HOST IMMUNITY TO EBV INFECTION IN VITRO AND IN VIVOR01AI018757 · NIAID · TUFTS UNIVERSITY BOSTON · PI POLTORAK, ALEXANDER · 1985 to 2017
$6.7M
EPSTEIN BARR VIRUS LATENCYR01CA065883 · NCI · TUFTS UNIVERSITY BOSTON · PI THORLEY-LAWSON, DAVID A. · 1995 to 2014
$4.3M
Computer Simulation of Epstein Barr Virus InfectionR01AI062989 · NIAID · TUFTS UNIVERSITY BOSTON · PI THORLEY-LAWSON, DAVID A. · 2005 to 2009
$2.2M
Light Weight Modeling of Epstein Barr VirusK25AI079404 · NIAID · TUFTS UNIVERSITY BOSTON · PI SHAPIRO, MICHAEL D. · 2008 to 2012
$623k
NCI NIH HHS R01 CA065883NCI NIH HHS R01 CA65883NIAID NIH HHS K25 AI079404NIAID NIH HHS K25-AI079404NIAID NIH HHS R01 AI018757NIAID NIH HHS R01 AI062989NIAID NIH HHS R01 AI18757
6 · The paper itself

Abstract

We have performed the first extensive profiling of Epstein-Barr virus (EBV) miRNAs on in vivo derived normal and neoplastic infected tissues. We describe a unique pattern of viral miRNA expression by normal infected cells in vivo expressing restricted viral latency programs (germinal center: Latency II and memory B: Latency I/0). This includes the complete absence of 15 of the 34 miRNAs profiled. These consist of 12 BART miRNAs (including approximately half of Cluster 2) and 3 of the 4 BHRF1 miRNAs. All but 2 of these absent miRNAs become expressed during EBV driven growth (Latency III). Furthermore, EBV driven growth is accompanied by a 5-10 fold down regulation in the level of the BART miRNAs expressed in germinal center and memory B cells. Therefore, Latency III also expresses a unique pattern of viral miRNAs. We refer to the miRNAs that are specifically expressed in EBV driven growth as the Latency III associated miRNAs. In EBV associated tumors that employ Latency I or II (Burkitt's lymphoma, Hodgkin's disease, nasopharyngeal carcinoma and gastric carcinoma), the Latency III associated BART but not BHRF1 miRNAs are up regulated. Thus BART miRNA expression is deregulated in the EBV associated tumors. This is the first demonstration that Latency III specific genes (the Latency III associated BARTs) can be expressed in these tumors. The EBV associated tumors demonstrate very similar patterns of miRNA expression yet were readily distinguished when the expression data were analyzed either by heat-map/clustering or principal component analysis. Systematic analysis revealed that the information distinguishing the tumor types was redundant and distributed across all the miRNAs. This resembles "secret sharing" algorithms where information can be distributed among a large number of recipients in such a way that any combination of a small number of recipients is able to understand the message. Biologically, this may be a consequence of functional redundancy between the miRNAs.

Indexed as

AnimalsB-LymphocytesCell Line, TumorDown-RegulationGene Expression ProfilingGene Expression Regulation, ViralHerpesvirus 4, HumanHumansMiceMicroRNAsMultigene FamilyNeoplasmsUp-RegulationViral ProteinsVirus LatencyBHRF1 protein, Human herpesvirus 4MicroRNAsViral Proteins

Identifiers

PMID21901094
PMCPMC3161978
OpenAlexW2038381426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.